Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer.

Literature DB >> 15064303

Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer.

Fernand Labrie¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2004 PMID： 15064303 DOI： 10.1002/j.1939-4640.2004.tb02791.x

Source DB: PubMed Journal: J Androl ISSN： 0196-3635

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.

Authors: C-T Wu; Y-H Yang; P-C Chen; M-F Chen; W-C Chen
Journal: Osteoporos Int Date: 2015-05-20 Impact factor: 4.507

2. Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.

Authors: A Dragomir; J Rocha; M Vanhuyse; F L Cury; W Kassouf; J Hu; A G Aprikian
Journal: Curr Oncol Date: 2017-08-31 Impact factor: 3.677

3. Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.

Authors: Kevin Shoulars; Mary Ann Rodriguez; Trellis Thompson; Barry M Markaverich
Journal: J Steroid Biochem Mol Biol Date: 2009-10-27 Impact factor: 4.292

4. Versatile virus-like particle carrier for epitope based vaccines.

Authors: Alain C Tissot; Regina Renhofa; Nicole Schmitz; Indulis Cielens; Edwin Meijerink; Velta Ose; Gary T Jennings; Philippe Saudan; Paul Pumpens; Martin F Bachmann
Journal: PLoS One Date: 2010-03-23 Impact factor: 3.240

Review 5. Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.

Authors: Davide Meani; Mladen Solarić; Harri Visapää; Rose-Marie Rosén; Robert Janknegt; Majana Soče
Journal: Ther Adv Urol Date: 2017-11-23

Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer.

1. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.

2. Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.

3. Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.

4. Versatile virus-like particle carrier for epitope based vaccines.

Review 5. Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.

6. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.

7. Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.

Review 8. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.